Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
about
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Hepatotoxicity Secondary to ChemotherapyA design for phase I trials in completely or partially ordered groups.Designs for phase I trials in ordered groups.A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials.Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple MyelomaThe use of novel agents in multiple myeloma patients with hepatic impairment.Bortezomib in mantle cell lymphoma: comparative therapeutic outcomesBortezomib for the treatment of non-Hodgkin's lymphomaPharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairmentPharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Bortezomib for the treatment of previously untreated multiple myeloma.Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides.Bortezomib: A Review in Mantle Cell Lymphoma in Previously Untreated Patients Unsuitable for Stem-Cell Transplantation.Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics.The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects.Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma.Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.Isotonic designs for phase I trials in partially ordered groups.Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.Bortezomib for the treatment of acute lymphoblastic leukemiaPharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
P2860
Q26741201-FF1209A6-1F04-4D96-8405-0DBAFA855549Q26861560-6F342787-6F67-4799-859F-FA884A35AE26Q30252706-C8F02287-E91F-4697-A5AC-5E80CFA34F9AQ30275947-E7B03183-5E3E-42C5-89DD-D6392BDDF649Q30299964-8D6AFE7F-6B82-46C8-AB82-43861B79B3DEQ31050273-8EA32FB3-4B3F-4716-B91D-4B23D9525B2CQ33418300-07C90129-98DF-4A19-A125-8E59104C534DQ33442798-4BFBC3A4-50C6-4DBD-AEFA-72371CC71E25Q33864685-4F9ABE83-F8B8-43AF-8552-C60FAD1B33ABQ34996710-77EBBBB7-3C6D-45F6-81EC-BC3A5B66F2D6Q35063100-F58CFE06-283F-4708-BA28-F12DC9731153Q35182819-5237263A-4644-43F8-A255-415EE0DE9CDBQ36278006-C82C4B6C-52EC-4FE9-AF23-B6EF3AFA3C03Q36868056-4B99CEBD-4DA3-47D6-A3F9-C6D6054DF140Q37384878-7B21DBB0-BA13-4967-9254-E288E7A509D3Q37386171-6B3F835C-A442-4AA2-A0DC-F4AFBDF48EF7Q38082728-CBB23540-A00D-4A05-A312-68AD7A874A1BQ38096055-B176100E-E6D1-453F-AD0F-96D4D1C09751Q38110433-1B68541D-4987-4C00-A69C-DB81D3CC8402Q38538693-FA3C4B32-C756-4515-8553-CBEE6E6DC3AAQ38803038-211F0619-948E-41CB-B20E-9C8F8227E4AFQ38866096-165CB42F-2212-4EFA-A11A-065EE9614B29Q38970962-CF4F37FA-C317-4BAF-868C-79C00E703BFEQ39115623-9641E7AD-3524-4F87-A5FB-2157DC13E6D8Q42281121-FA635BCA-E4FB-48C0-986A-FC90AB338A86Q42684972-FDAB3E74-DC0B-482D-849E-75476144E467Q45064728-262565A2-A2C4-47DE-913A-6F0A61F48AEBQ47628307-8237D055-CE08-4ED7-B404-E876D9123A87Q47990284-A124C2B0-D7AC-4796-BDD2-C2E6CF901E44Q54323723-14EB177E-B4B0-4AAC-BC2F-D30B47C20E94Q57286691-6A850579-E2FC-4723-9D21-98E82D207DC4Q58099961-96D2B328-5AF3-4C3C-81C5-2F0C23BF8BA4
P2860
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@en
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@nl
type
label
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@en
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@nl
prefLabel
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@en
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@nl
P2093
P2860
P1476
Pharmacokinetics and safety of ...... Working Group Study NCI-6432.
@en
P2093
Afshin Dowlati
Anne Hamilton
Chris H Takimoto
Daniel Mulkerin
Dixie-Lee Esseltine
John Sarantopoulos
Karthik Venkatakrishnan
Michelle A Rudek
Patricia M LoRusso
P2860
P304
P356
10.1158/1078-0432.CCR-11-2873
P407
P577
2012-03-06T00:00:00Z